Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. [electronic resource]
Producer: 20201230Description: 60-67 p. digitalISSN:- 1872-8332
- Adenocarcinoma of Lung -- drug therapy
- Benzamides -- therapeutic use
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Drug Resistance, Neoplasm -- drug effects
- Female
- Focal Adhesion Protein-Tyrosine Kinases -- antagonists & inhibitors
- Follow-Up Studies
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Mutation
- Prognosis
- Prospective Studies
- Proto-Oncogene Proteins p21(ras) -- genetics
- Pyrazines -- therapeutic use
- Salvage Therapy
- Sulfonamides -- therapeutic use
- Survival Rate
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.